Endocan, obstructive sleep apnea, and vascular risk

Angiology

Volumn 67, Issue 4, 2016, Pages 305-306

  Balta, Sevket ^a   Ozturk, Cengiz ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ENDOCAN; PROTEIN; UNCLASSIFIED DRUG; ESM1 PROTEIN, HUMAN; PROTEOGLYCAN; TUMOR PROTEIN;

ACUTE CORONARY SYNDROME; ANGIOGENESIS; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ADHESION; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; EDITORIAL; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; HYPERTENSION; POSITIVE END EXPIRATORY PRESSURE; SLEEP DISORDERED BREATHING; ANIMAL; BLOOD; COMPLICATION; METABOLISM; PATHOPHYSIOLOGY; RISK; VASCULAR DISEASES;

ANIMALS; ENDOTHELIAL CELLS; HUMANS; NEOPLASM PROTEINS; PROTEOGLYCANS; RISK; SLEEP APNEA, OBSTRUCTIVE; VASCULAR DISEASES;

EID: 84959303495     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319715591332     Document Type: Editorial

References (23)

1. Katsiki N, Athyros VG, Karagiannis A, Wierzbicki AS, Mikhailidis DP,. Should we expand the concept of coronary heart disease equivalents? Curr Opin Cardiol. 2014; 29 (4): 389-395.
2. Drager LF, Polotsky VY, Lorenzi-Filho G,. Obstructive sleep apnea: an emerging risk factor for atherosclerosis. Chest. 2011; 140 (2): 534-542.
3. Nena E, Papanas N, Steiropoulos P, et al. Mean Platelet Volume and Platelet Distribution Width in non-diabetic subjects with obstructive sleep apnoea syndrome: new indices of severity? Platelets. 2012; 23 (6): 447-454.
4. Anandam A, Patil M, Akinnusi M, Jaoude P, El-Solh AA,. Cardiovascular mortality in obstructive sleep apnoea treated with continuous positive airway pressure or oral appliance: an observational study. Respirology. 2013; 18 (8): 1184-1190.
5. Holmqvist F, Guan N, Zhu Z, et al. Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation-Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2015; 169 (5): 647-654. e2.
6. Sánchez-de-la-Torre M, Nadal N, Cortijo A, et al. Role of primary care in the follow-up of patients with obstructive sleep apnoea undergoing CPAP treatment: a randomised controlled trial. Thorax. 2015; 70 (4): 346-352.
7. Altintas N, Mutlu L, Akkoyun D, et al. Effect of CPAP on new endothelial function marker; endocan in people with obstructive sleep apnea. Angiology. doi: 10.1177/0003319715590558.
8. Balta S, Ozturk C,. The relation between CD40 ligand and coronary artery disease. Cardiology. 2015; 131 (2): 107-108.
9. Balta I, Balta S, Koryurek OM, et al. Mean platelet volume is associated with aortic arterial stiffness in patients with Behçet's disease without significant cardiovascular involvement. J Eur Acad Dermatol Venereol. 2014; 28 (10): 1388-1393.
10. Lee W, Ku S-K, Kim S-W, Bae J-S,. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014; 229 (5): 620-630.
11. Sarrazin S, Adam E, Lyon M, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta. 2006; 1765 (1): 25-37.
12. Kali A, Shetty KSR,. Endocan: a novel circulating proteoglycan. Indian J Pharmacol. 2014; 46 (6): 579-583.
13. Bechard D, Meignin V, Scherpereel A, et al. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res. 2000; 37 (5): 417-425.
14. Balta S, Mikhailidis DP, Demirkol S, et al. Endocan-a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014; 65 (9): 773-777.
15. Gonzaga C, Bertolami A, Bertolami M, Amodeo C, Calhoun D,. Obstructive sleep apnea, hypertension and cardiovascular diseases. J Hum Hypertens. 2015. doi:10.1038/jhh.2015.15.
16. Wang X-S, Yang W, Luo T, Wang J-M, Jing Y-Y,. Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet Test Mol Biomarkers. 2015; 19 (3): 124-127.
17. Kose M, Emet S, Akpinar TS, et al. Serum endocan level and the severity of coronary artery disease: a pilot study. Angiology. doi: 10.1177/0003319714548870.
18. Yilmaz MI, Siriopol D, Saglam M, et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int. 2014; 86 (6): 1213-1220.
19. Balta I, Balta S, Koryurek OM, et al. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol. 2014; 70 (2): 291-296.
20. Gowda S, Goldblum OM, McCall WV, Feldman SR,. Factors affecting sleep quality in patients with psoriasis. J Am Acad Dermatol. 2010; 63 (1): 114-123.
21. Balta I, Balta S, Demirkol S, et al. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol. 2013; 169 (5): 1066-1070.
22. Katsiki N, Anagnostis P, Athyros VG, Karagiannis A, Mikhailidis DP,. Psoriasis and vascular risk: an update. Curr Pharm Des. 2014; 20 (39): 6114-6125.
23. Cellk T, Balta S, Karaman M, et al. Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan. Blood Press. 2015; 24 (1): 55-60.